Menu
Team Veye   January 20, 2026

China good news boosts this ASX healthcare stock

Team Veye   January 20, 2026
Get your Free Report on Top 5 ASX stocks for 2026

Telix Pharmaceuticals on Tuesday announced that the Chinese NMPA accepted the New Drug Application for Illuccix and this marks a major regulatory milestone in the company’s global expansion journey.

Telix Pharmaceuticals Limited (ASX: TLX)

on 20 January 2026 announced that Chinese National Medical Products Administration (NMPA) has accepted the New Drug Application for Illuccix which is its lead prostate cancer imaging agent.
The Illuccix China study reported an overall patient level positive predictive value (PPV) of 94.8% for tumour detection in patients experiencing biochemical recurrence (BCR) of prostate cancer.

More than 67% of patients experienced a change in treatment plans due to Illuccix imaging which highlights strong clinical impact and reinforces China as a major new commercial opportunity for Telix.

The company on 17 December 2025 confirmed completion of Part 1 enrolment in the global Phase 3 ProstACT study for its therapeutic candidate TLX591.

Following a positive safety review by the Independent Data Monitoring Committee, ProstACT advanced into Part 2 and began dosing patients across approved jurisdictions.

This trial is the first Phase 3 study combining a PSMA targeted radio antibody therapy with standard of care treatments in metastatic castration resistant prostate cancer.
For Q3 2025, group revenue reached US$206 million which is up 53% year-on-year and was supported by solid sales of Illuccix and Gozellix.

FY25 revenue guidance was increased to US$800 to 820 million which reflects strong global demand and the company also secured full U.S. reimbursement for Gozellix under HCPCS Level II and TPT status from 1 October 2025 which improves accessibility and supports further growth in North America.

Telix has a market capitalisation of $3.87 billion and has favourable conditions in place as expanding global reimbursement, several late-stage clinical trials and rising adoption of its PSMA imaging products provide strong momentum.

(Source: Company Announcements)

Get your FREE ASX stock report

Discover our latest ASX share ideas and ongoing insights – so you're not guessing with your money

💬

Get Your Free Report on Top 5 ASX Stocks on WhatsApp

Instant Access. No Credit Card Required.

Receive on WhatsApp

Checkout Our Recommendation for free - 7 days free trial

Start Free Trial
7‑day free trial

ASX Stock Research & Recommendations — 7‑day free trial

Independent, analyst‑driven insights.

  • Stock of the week report
  • Daily Analysis Report
  • No credit card required
General information only. Not financial advice.

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.